{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:52:35Z","timestamp":1780570355628,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Graduate school of pharmacy, University of Eastern Finland"},{"name":"Finnish Pharmaceutical Society"},{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["311122"],"award-info":[{"award-number":["311122"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R181-2014- 3577"],"award-info":[{"award-number":["R181-2014- 3577"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sokeain Yst\u00e4v\u00e4t \u2013 De Blindas V\u00e4nner sr"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To estimate the diffusion coefficients of an IgG antibody (150\u00a0kDa) and its antigen-binding fragment (Fab; 50\u00a0kDa) in the neural retina (D<jats:sub>ret<\/jats:sub>) and the combined retinal pigment epithelium-choroid (D<jats:sub>RPE-cho<\/jats:sub>) with a 3-dimensional (3D) ocular pharmacokinetic (PK) model of the rabbit eye.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Vitreous, retina, and aqueous humor concentrations of IgG and Fab after intravitreal injection in rabbits were taken from Gadkar et al. (2015). A least-squares method was used to estimate D<jats:sub>ret<\/jats:sub> and D<jats:sub>RPE-cho<\/jats:sub> with the 3D finite element model where mass transport was defined with diffusion and convection. Different intraocular pressures (IOP), initial distribution volumes (V<jats:sub>init<\/jats:sub>), and neural retina\/vitreous partition coefficients (K<jats:sub>ret\/vit<\/jats:sub>) were tested. Sensitivity analysis was performed for the final model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With the final IgG model (IOP 10.1\u00a0Torr, V<jats:sub>init<\/jats:sub> 400\u00a0\u03bcl, K<jats:sub>ret\/vit<\/jats:sub> 0.5), the estimated D<jats:sub>ret<\/jats:sub> and D<jats:sub>RPE-cho<\/jats:sub> were 36.8\u2009\u00d7\u200910<jats:sup>\u22129<\/jats:sup> cm<jats:sup>2<\/jats:sup>s<jats:sup>\u22121<\/jats:sup> and 4.11\u2009\u00d7\u200910<jats:sup>\u22129<\/jats:sup> cm<jats:sup>2<\/jats:sup>s<jats:sup>\u22121<\/jats:sup>, respectively, and 76% of the dose was eliminated via the anterior chamber. Modeling of Fab revealed that a physiological model parameter \u201caqueous humor formation rate\u201d sets constraints that need to be considered in the parameter estimation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study extends the use of 3D ocular PK models for parameter estimation using simultaneously macromolecule concentrations in three ocular tissues.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11095-020-02946-1","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T17:03:04Z","timestamp":1603386184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Extended Pharmacokinetic Model of the Intravitreal Injections of Macromolecules in Rabbits. Part 2: Parameter Estimation Based on Concentration Dynamics in the Vitreous, Retina, and Aqueous Humor"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-3128","authenticated-orcid":false,"given":"Marko","family":"Lamminsalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Karvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Subrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto","family":"Urtti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli-Pekka","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"11","key":"2946_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","volume":"58","author":"A Urtti","year":"2006","unstructured":"Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131\u20135.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2946_CR2","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1167\/iovs.10-5392","volume":"51","author":"HF Edelhauser","year":"2010","unstructured":"Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403\u201320.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2946_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM del Amo","year":"2017","unstructured":"del Amo EM, Rimpel\u00e4 AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134\u201385.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"2946_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398.","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"2946_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/ICU.0000000000000657","volume":"31","author":"MJ Ammar","year":"2020","unstructured":"Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol. 2020;31(3):215\u201321.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"2946_CR6","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5):CD012208.","journal-title":"Cochrane Database Syst Rev"},{"key":"2946_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/OPTH.S236637","volume":"14","author":"SE Mansour","year":"2020","unstructured":"Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020;14:653\u201378.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"2946_CR8","first-page":"253","volume":"26","author":"S Kiss","year":"2020","unstructured":"Kiss S, Malangone-Monaco E, Wilson K, Varker H, Stetsovsky D, Smith D, et al. Real-world injection frequency and cost of Ranibizumab and Aflibercept for the treatment of Neovascular age-related macular degeneration and diabetic macular edema. J Manag Care Spec Pharm. 2020;26(3):253\u201366.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2946_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3928\/23258160-20200228-01","volume":"51","author":"D Levine","year":"2020","unstructured":"Levine D, Albini TA, Fine HF, Yeh S. Emerging drug delivery Systems for Posterior Segment Disease. Ophthalmic Surg Lasers Imaging Retina. 2020;51(3):132\u20135.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2946_CR10","doi-asserted-by":"publisher","unstructured":"Meza-Rios A, Navarro-Partida J, Armendariz-Borunda J, Santos A. Therapies based on nanoparticles for eye drug delivery. Ophthalmol Ther. 2020 may 7. https:\/\/doi.org\/10.1007\/s40123-020-00257-7. Online ahead of print.","DOI":"10.1007\/s40123-020-00257-7"},{"key":"2946_CR11","doi-asserted-by":"crossref","unstructured":"del Amo EM, Vellonen KS, Kidron H, Urtti A. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. Eur J Pharm Biopharm. 2015;95(Pt B):215\u201326.","DOI":"10.1016\/j.ejpb.2015.01.003"},{"issue":"2","key":"2946_CR12","first-page":"695","volume":"17","author":"A Caruso","year":"2020","unstructured":"Caruso A, F\u00fcth M, Alvarez-S\u00e1nchez R, Belli S, Diack C, Maass KF, et al. Ocular half-life of Intravitreal biologics in humans and other species: meta-analysis and model-based prediction. Mol Pharm. 2020;17(2):695\u2013709.","journal-title":"Mol Pharm"},{"key":"2946_CR13","first-page":"16","volume-title":"Handbook of experimental pharmacology","author":"DM Maurice","year":"1984","unstructured":"Maurice DM, Mishima S. Ocular pharmacology. In: Sears M, editor. Handbook of experimental pharmacology. Berlin-Heidelberg: Springer-Verlag; 1984. p. 16\u2013119."},{"key":"2946_CR14","first-page":"59","volume-title":"Symposium on ocular therapy","author":"DM Maurice","year":"1976","unstructured":"Maurice DM. Injection of drugs into the vitreous body. In: Leopold I, Burns R, editors. Symposium on ocular therapy, vol. 9. London: Wiley; 1976. p. 59\u201372."},{"issue":"8","key":"2946_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11095-018-2435-0","volume":"35","author":"M Lamminsalo","year":"2018","unstructured":"Lamminsalo M, Taskinen E, Karvinen T, Subrizi A, Murtom\u00e4ki L, Urtti A, et al. Extended pharmacokinetic model of the rabbit eye for Intravitreal and Intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways. Pharm Res. 2018;35(8):153.","journal-title":"Pharm Res"},{"issue":"8","key":"2946_CR16","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","volume":"14","author":"LA Hutton-Smith","year":"2017","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Gadkar K, Mazer NA. Ocular pharmacokinetics of therapeutic antibodies given by Intravitreal injection: estimation of retinal Permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm. 2017;14(8):2690\u20136.","journal-title":"Mol Pharm"},{"issue":"1","key":"2946_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-4835(91)90125-X","volume":"52","author":"M Araie","year":"1991","unstructured":"Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res. 1991;52(1):27\u201339.","journal-title":"Exp Eye Res"},{"issue":"9","key":"2946_CR18","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","volume":"13","author":"LA Hutton-Smith","year":"2016","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Schwab D, Mazer NA. A mechanistic model of the Intravitreal pharmacokinetics of large molecules and the Pharmacodynamic suppression of ocular vascular endothelial growth factor levels by Ranibizumab in patients with Neovascular age-related macular degeneration. Mol Pharm. 2016;13(9):2941\u201350.","journal-title":"Mol Pharm"},{"issue":"1","key":"2946_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","volume":"11","author":"AK Rimpel\u00e4","year":"2018","unstructured":"Rimpel\u00e4 AK, Kiiski I, Deng F, Kidron H, Urtti A. Pharmacokinetic simulations of Intravitreal Biologicals: aspects of drug delivery to the posterior and anterior segments. Pharmaceutics. 2018;11(1):9.","journal-title":"Pharmaceutics."},{"issue":"12","key":"2946_CR20","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","volume":"29","author":"PJ Missel","year":"2012","unstructured":"Missel PJ. Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes. Pharm Res. 2012;29(12):3251\u201372.","journal-title":"Pharm Res"},{"issue":"12","key":"2946_CR21","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.1167\/iovs.17-23632","volume":"59","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Bazzazi H, Lima E, Silva R, Pandey NB, Green JJ, et al. Three-dimensional transport model for Intravitreal and Suprachoroidal drug injection. Invest Ophthalmol Vis Sci. 2018;59(12):5266\u201376.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2946_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0025-5564(94)90018-3","volume":"123","author":"KJ Tojo","year":"1994","unstructured":"Tojo KJ, Ohtori A. Pharmacokinetic model of intravitreal drug injection. Math Biosci. 1994;123(1):59\u201375.","journal-title":"Math Biosci"},{"key":"2946_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mbs.2014.06.008","volume":"255","author":"E Jooybar","year":"2014","unstructured":"Jooybar E, Abdekhodaie MJ, Farhadi F, Cheng YL. Computational modeling of drug distribution in the posterior segment of the eye: effects of device variables and positions. Math Biosci. 2014;255:11\u201320.","journal-title":"Math Biosci"},{"issue":"8","key":"2946_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.drudis.2019.05.039","volume":"24","author":"PJ Missel","year":"2019","unstructured":"Missel PJ, Sarangapani R. Physiologically based ocular pharmacokinetic modeling using computational methods. Drug Discov Today. 2019;24(8):1551\u201363.","journal-title":"Drug Discov Today"},{"issue":"1","key":"2946_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11095-012-0847-9","volume":"30","author":"N Haghjou","year":"2013","unstructured":"Haghjou N, Abdekhodaie MJ, Cheng Y. Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment. Pharm Res. 2013;30(1):41\u201359.","journal-title":"Pharm Res"},{"issue":"9","key":"2946_CR26","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1167\/iovs.15-17108","volume":"56","author":"K Gadkar","year":"2015","unstructured":"Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, et al. Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics. Invest Ophthalmol Vis Sci. 2015;56(9):5390\u2013400.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2946_CR27","volume-title":"Transport phenomena. Revised 2nd edition","author":"RB Bird","year":"2007","unstructured":"Bird RB, Stewart WE, Lightfoot EN. Transport phenomena. Revised 2nd edition. New York: John Wiley & Sons, Inc.; 2007."},{"issue":"9","key":"2946_CR28","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1021\/acs.molpharmaceut.6b00345","volume":"13","author":"W Shatz","year":"2016","unstructured":"Shatz W, Hass PE, Mathieu M, Kim HS, Leach K, Zhou M, et al. Contribution of antibody hydrodynamic size to Vitreal clearance revealed through rabbit studies using a species-matched fab. Mol Pharm. 2016;13(9):2996\u20133003.","journal-title":"Mol Pharm"},{"key":"2946_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mehy.2016.11.017","volume":"98","author":"R Chawla","year":"2017","unstructured":"Chawla R, Tripathy K, Temkar S, Kumar V. Internal limiting membrane: the innermost retinal barrier. Med Hypotheses. 2017;98:60\u20132.","journal-title":"Med Hypotheses"},{"key":"2946_CR30","doi-asserted-by":"publisher","unstructured":"Smith DW, Lee CJ, Gardiner BS. No flow through the vitreous humor: how strong is the evidence? Prog Retin Eye Res 2020 Feb 6:100845. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100845. Online ahead of print.","DOI":"10.1016\/j.preteyeres.2020.100845"},{"issue":"10","key":"2946_CR31","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.bpj.2015.10.002","volume":"109","author":"BT K\u00e4sdorf","year":"2015","unstructured":"K\u00e4sdorf BT, Arends F, Lieleg O. Diffusion regulation in the vitreous humor. Biophys J. 2015;109(10):2171\u201381.","journal-title":"Biophys J"},{"issue":"1","key":"2946_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","volume":"167","author":"Q Xu","year":"2013","unstructured":"Xu Q, Boylan NJ, Suk JS, Wang YY, Nance EA, Yang JC, et al. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J Control Release. 2013;167(1):76\u201384.","journal-title":"J Control Release"},{"issue":"12","key":"2946_CR33","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.2217\/nnm.12.202","volume":"8","author":"TF Martens","year":"2013","unstructured":"Martens TF, Vercauteren D, Forier K, Deschout H, Remaut K, Paesen R, et al. Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy. Nanomedicine (Lond). 2013;8(12):1955\u201368.","journal-title":"Nanomedicine (Lond)"},{"key":"2946_CR34","doi-asserted-by":"publisher","unstructured":"Tavakoli S, Kari OK, Turunen T, Lajunen T, Schmitt M, Lehtinen J, et al. Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations [published online ahead of print, 2020 Jul 8]. Mol Pharm. 2020; https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00411.","DOI":"10.1021\/acs.molpharmaceut.0c00411"},{"issue":"2","key":"2946_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1167\/iovs.04-1051","volume":"46","author":"L Pitk\u00e4nen","year":"2005","unstructured":"Pitk\u00e4nen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46(2):641\u20136.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-020-02946-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:36:19Z","timestamp":1634859379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-020-02946-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02946-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"226"}}